Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 18;12(1):e055572.
doi: 10.1136/bmjopen-2021-055572.

Use of the kidney failure risk equation to inform clinical care of patients with chronic kidney disease: a mixed-methods systematic review

Harjeet Kaur Bhachu  1   2   3 , Anthony Fenton  4   2 , Paul Cockwell  1   5 , Olalekan Aiyegbusi  2   3   6   7 , Derek Kyte  2   3   8 , Melanie Calvert  2   3   6   7
Affiliations

Use of the kidney failure risk equation to inform clinical care of patients with chronic kidney disease: a mixed-methods systematic review

Harjeet Kaur Bhachu et al. BMJ Open. .

Abstract

Rationale and objective: The Kidney Failure Risk Equation (KFRE) predicts the risk of end-stage kidney disease in patients with chronic kidney disease (CKD). This study aimed to evaluate the impact of the utility of KFRE in clinical practice.

Study design: Systematic review.

Setting and study populations: Adult patients with CKD but not receiving renal replacement therapy enrolled in studies where KFRE was used in clinical care pathways.

Selection criteria for studies: All studies published from April 2011 to October 2021 identified from Medline, Cumulative Index to Nursing and Allied Health Literature, Embase and reference and citation searches of included studies.

Data extraction: Relevant data were extracted, and two reviewers independently assessed study quality using appropriate appraisal tools.

Analytical approach: Findings reported as a narrative synthesis due to heterogeneity of the included studies.

Results: Of 1635 studies identified, 440 duplicates were removed. The remaining 1195 titles and abstracts were screened. All five studies for full-text review were included in the analysis. Three uses of KFRE were assessed: (1) primary to specialty care interface; (2) general nephrology to multidisciplinary care transition; and (3) treatment planning. Evidence of impact on number of patient referrals into nephrology care was conflicting. However, wait times improved in one study. Although KFRE identified high-risk patients for increased multidisciplinary support, there was concern patients stepped down, no longer meeting eligibility criteria, may lack access to services.

Conclusions: This is the first systematic review of studies that have assessed the actual impact of KFRE in clinical practice with five studies of varying quality reported to date. Trials are in progress assessing the impact on clinical outcomes of using KFRE in clinical practice, and KFRE is being incorporated into guidelines for CKD management. Further studies are needed to assess the impact of KFRE on clinical care.

Trial registration number: Protocol registered on PROSPERO before initiation of the study (Ref: CRD42020219926).

Keywords: chronic renal failure; dialysis; end stage renal failure; renal transplantation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PC reports grants from Kidney Research UK, National Institute for Health Research (NIHR), MRC and EU Horizon 20/20 programme, and personal fees from NAPP Pharmaceuticals outside the submitted work. OA receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Applied Research Centre (ARC), West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd and Janssen Pharmaceuticals, Inc. OLA declares personal fees from Gilead Sciences Ltd, GlaxoSmithKline (GSK) and Merck outside the submitted work. DK reports grants from Macmillan Cancer Support, Innovate UK, the NIHR, NIHR Birmingham Biomedical Research Centre and NIHR SRMRC at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, and personal fees from Merck and GSK outside the submitted work. MC is an NIHR Senior Investigator and receives funding from the NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma and GSK. MC has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work.

Figures

Figure 1
Figure 1
Flow diagram to show the studies identified from searches.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bikbov B, Purcell CA, Levey AS, et al. . Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2020;395:709–33. 10.1016/S0140-6736(20)30045-3 - DOI - PMC - PubMed
    1. Daker-White G, Rogers A, Kennedy A, et al. . Non-disclosure of chronic kidney disease in primary care and the limits of instrumental rationality in chronic illness self-management. Soc Sci Med 2015;131:31–9. 10.1016/j.socscimed.2015.02.035 - DOI - PubMed
    1. Smekal MD, Tam-Tham H, Finlay J, et al. . Patient and provider experience and perspectives of a risk-based approach to multidisciplinary chronic kidney disease care: a mixed methods study. BMC Nephrol 2019;20. 10.1186/s12882-019-1269-2 - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence (UK) . Chronic kidney disease in adults: assessment and management (CG182). London: National Institute for Health and Care Excellence (UK), 2014.
    1. Bhachu HK, Cockwell P, Subramanian A, et al. . Impact of using Risk-Based stratification on referral of patients with chronic kidney disease from primary care to specialist care in the United Kingdom. Kidney Int Rep 2021;6:2189–99. 10.1016/j.ekir.2021.05.031 - DOI - PMC - PubMed

Publication types